94 related articles for article (PubMed ID: 20088516)
1. De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
Nugiel DA; Krumrine JR; Hill DC; Damewood JR; Bernstein PR; Sobotka-Briner CD; Liu J; Zacco A; Pierson ME
J Med Chem; 2010 Feb; 53(4):1876-80. PubMed ID: 20088516
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).
Bromidge SM; Arban R; Bertani B; Bison S; Borriello M; Cavanni P; Dal Forno G; Di-Fabio R; Donati D; Fontana S; Gianotti M; Gordon LJ; Granci E; Leslie CP; Moccia L; Pasquarello A; Sartori I; Sava A; Watson JM; Worby A; Zonzini L; Zucchelli V
J Med Chem; 2010 Aug; 53(15):5827-43. PubMed ID: 20590088
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.
Ward SE; Harrington FP; Gordon LJ; Hopley SC; Scott CM; Watson JM
J Med Chem; 2005 May; 48(10):3478-80. PubMed ID: 15887956
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation, and docking studies of tetrahydrofuran- cyclopentanone- and cyclopentanol-based ligands acting at adrenergic α₁- and serotonine 5-HT1A receptors.
Prandi A; Franchini S; Manasieva LI; Fossa P; Cichero E; Marucci G; Buccioni M; Cilia A; Pirona L; Brasili L
J Med Chem; 2012 Jan; 55(1):23-36. PubMed ID: 22145629
[TBL] [Abstract][Full Text] [Related]
5. 8-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors--part II.
Bromidge SM; Bertani B; Borriello M; Bozzoli A; Faedo S; Gianotti M; Gordon LJ; Hill M; Zucchelli V; Watson JM; Zonzini L
Bioorg Med Chem Lett; 2009 Apr; 19(8):2338-42. PubMed ID: 19286377
[TBL] [Abstract][Full Text] [Related]
6. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
[TBL] [Abstract][Full Text] [Related]
8. (3-Phenylsulfonylcycloalkano[e and d]pyrazolo[1,5-a]pyrimidin-2-yl)amines: potent and selective antagonists of the serotonin 5-HT6 receptor.
Ivachtchenko AV; Dmitriev DE; Golovina ES; Kadieva MG; Koryakova AG; Kysil VM; Mitkin OD; Okun IM; Tkachenko SE; Vorobiev AA
J Med Chem; 2010 Jul; 53(14):5186-96. PubMed ID: 20560595
[TBL] [Abstract][Full Text] [Related]
9. 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.
Procopiou PA; Ancliff RA; Bamford MJ; Browning C; Connor H; Davies S; Fogden YC; Hodgson ST; Holmes DS; Looker BE; Morriss KM; Parr CA; Pickup EA; Sehmi SS; White GV; Watts CJ; Wilson DM; Woodrow MD
J Med Chem; 2007 Dec; 50(26):6706-17. PubMed ID: 18052318
[TBL] [Abstract][Full Text] [Related]
10. Zwitterionic CRTh2 antagonists.
Luker T; Bonnert R; Paine SW; Schmidt J; Sargent C; Cook AR; Cook A; Gardiner P; Hill S; Weyman-Jones C; Patel A; Thom S; Thorne P
J Med Chem; 2011 Mar; 54(6):1779-88. PubMed ID: 21355602
[TBL] [Abstract][Full Text] [Related]
11. Preparation of piperazine derivatives as 5-HT7 receptor antagonists.
Yoon J; Yoo EA; Kim JY; Pae AN; Rhim H; Park WK; Kong JY; Park Choo HY
Bioorg Med Chem; 2008 May; 16(10):5405-12. PubMed ID: 18456500
[TBL] [Abstract][Full Text] [Related]
12. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
[TBL] [Abstract][Full Text] [Related]
13. Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Butini S; Campiani G; Franceschini S; Trotta F; Kumar V; Guarino E; Borrelli G; Fiorini I; Novellino E; Fattorusso C; Persico M; Orteca N; Sandager-Nielsen K; Jacobsen TA; Madsen K; Scheel-Kruger J; Gemma S
J Med Chem; 2010 Jun; 53(12):4803-7. PubMed ID: 20481570
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
[TBL] [Abstract][Full Text] [Related]
15. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI
J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448
[TBL] [Abstract][Full Text] [Related]
16. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
[TBL] [Abstract][Full Text] [Related]
17. Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.
Zech G; Hessler G; Evers A; Weiss T; Florian P; Just M; Czech J; Czechtizky W; Görlitzer J; Ruf S; Kohlmann M; Nazaré M
J Med Chem; 2012 Oct; 55(20):8615-29. PubMed ID: 22984835
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.
Childers WE; Abou-Gharbia MA; Kelly MG; Andree TH; Harrison BL; Ho DM; Hornby G; Huryn DM; Potestio L; Rosenzweig-Lipson SJ; Schmid J; Smith DL; Sukoff SJ; Zhang G; Schechter LE
J Med Chem; 2005 May; 48(10):3467-70. PubMed ID: 15887953
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist.
Zhang M; Zhou D; Wang Y; Maier DL; Widzowski DV; Sobotka-Briner CD; Brockel BJ; Potts WM; Shenvi AB; Bernstein PR; Pierson ME
J Pharmacol Exp Ther; 2011 Nov; 339(2):567-78. PubMed ID: 21825000
[TBL] [Abstract][Full Text] [Related]
20. Novel aryloxy-8-azabicyclo[3.2.1]oct-3-enes with 5-HT transporter and 5-HT1A affinity.
Gilbert AM; Coleman T; Kodah J; Mewshaw RE; Scerni R; Schechter LE; Smith DL; Andree TH
Bioorg Med Chem Lett; 2004 Nov; 14(21):5281-4. PubMed ID: 15454211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
